Developing oncology therapies using CRISPR gene editing
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
250
NCT04163575
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Phase: Phase 1/2
Role: Lead Sponsor
Start: Feb 1, 2020
Completion: Jul 1, 2022
NCT05651100
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Start: Dec 10, 2022
Completion: Dec 10, 2025
NCT04100187
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Phase: Phase 1
Start: Feb 1, 2023
Completion: Aug 1, 2024